To the full analysis
Twist Bioscience stock: growth
TWSTTwist Bioscience reported $459.43M in revenue for fiscal 2026, up 22% on the prior year, up 28.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
70.1%
per year from 2016 to 2026, per share 50.8%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | |
|---|---|---|
| Revenue | 28.3% | 70.1% |
| Revenue per share | 21.8% | 50.8% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2016 | $2.27M | −$44.09M | −$44.82M |
| 2017 | $10.77M | −$59.31M | −$57.9M |
| 2018 | $25.43M | −$71.24M | −$69.85M |
| 2019 | $54.39M | −$107.67M | −$102.69M |
| 2020 | $90.1M | −$139.93M | −$152.12M |
| 2021 | $132.33M | −$152.1M | −$139.31M |
| 2022 | $203.57M | −$217.86M | −$226.24M |
| 2023 | $245.11M | −$204.62M | −$170.25M |
| 2024 | $312.97M | −$208.73M | −$69.17M |
| 2025 | $376.57M | −$77.67M | −$75.63M |
| 2026 | $459.43M | −$130.2M | $0 |
Revenue by segment
How Twist Bioscience Corporation makes its money and how that has shifted. Names are as the company reports them.
- Ngs Tools55%
- Synthetic Genes30%
- Antibody Discovery6%
- Oligo Pools5%
- Dna And Biopharma Libraries3%
Figures as a table
| 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|
| Ngs Tools | $99.31M | $123.71M | $169.13M | $208.1M | 55.3% |
| Synthetic Genes | $61.51M | $73.54M | $92.68M | $113.6M | 30.2% |
| Antibody Discovery | $24.17M | $23.17M | $20.33M | $23.45M | 6.2% |
| Oligo Pools | $12.42M | $14.49M | $16.91M | $20.23M | 5.4% |
| Dna And Biopharma Libraries | $6.15M | $10.2M | $13.93M | $11.18M | 3% |
| Total revenue | $203.57M | $245.11M | $312.97M | $376.57M | 100% |
Revenue by region
Where Twist Bioscience Corporation generates its revenue.
- Americas60%
- EMEA33%
- Asia Pacific7%
Figures as a table
| 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|
| Americas | $122.47M | $151.26M | $193.88M | $225.58M | 59.9% |
| EMEA | $62.08M | $71.39M | $92.57M | $124.24M | 33% |
| Asia Pacific | $19.01M | $22.46M | $26.52M | $26.75M | 7.1% |
| Total revenue | $203.57M | $245.11M | $312.97M | $376.57M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Sep 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 15 Oct 2026)
- Valuation signal Fairly valued since 13 Nov 2026, previously Overvalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.